Kamada to Announce Third Quarter Ended

Kamada to Announce Third Quarter Ended September

30, 2020 Financial Results and Host Conference Call on November 11, 2020

Rehovot, Israel, November 4, 2020 --

Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial

results for the third quarter ended September 30, 2020, prior to the open of the U.S. financial markets on Wednesday, November

Kamada management will host an investment community

conference call on Wednesday, November 11, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and

other interested parties may participate in the conference call by dialing 877-407-0792 (from within the U.S.), 1-809-406-247 (from

Israel), or 201-689-8263 (International) and entering the conference identification number: 13710863. The call will also be webcast

live on the Internet on the Company's website at www.kamada.com.

call will also be archived for 90 days on the Company's website at www.kamada.com.

Kamada Ltd. ("the Company") is

a commercial stage plasma-derived biopharmaceutical company focused on orphan indications, with an existing marketed product portfolio

and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification

of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived

immune globulins. The Company's flagship product is GLASSIA , the first liquid, ready-to-use, intravenous plasma-derived

AAT product approved by the U.S. FDA. The Company markets GLASSIA in the U.S. through a strategic partnership with Takeda Pharmaceuticals

Company Limited and in other countries through local distributors. Pursuant to an agreement with Takeda the Company will continue

to produce Glassia for Takeda through 2021 and Takeda is planning to initiate its own production of Glassia for the U.S. market

in 2021 at which point Takeda will commence payment of royalties to the Company. The Company's second leading product is

KamRab , a rabies immune globulin (Human) for post-exposure prophylaxis against rabies infection. KamRab is FDA approved and

is being marketed in the U.S. under the brand name KEDRAB through a strategic partnership with Kedrion S.p.A. In addition

to Glassia and KEDRAB, the Company has a product line of four other plasma-derived pharmaceutical products administered by injection

or infusion, that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, India and other

countries in Latin America and Asia. The Company has late-stage products in development, including an inhaled formulation of AAT

for the treatment of AAT deficiency. In addition, the Company's intravenous AAT is in development for other indications,

such as GvHD and prevention of lung transplant rejection, and during 2020, the Company initiated the development of a plasma derived

hyperimmune immunoglobulin (IgG) product as a potential treatment for coronavirus disease (COVID-19). The Company leverages its

expertise and presence in the plasma-derived protein therapeutics market by distributing more than 20 complementary products in

Israel that are manufactured by third parties. FIMI Opportunity Fund, the leading private equity investor in Israel, is the Company's

lead shareholder, beneficially owning approximately 21% of the outstanding ordinary shares.

Chief Financial Officer

LifeSci Advisors, LLC